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Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an
array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein
containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is
associated with pathogenesis but it is unclear how.
Methods: Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined.
Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and
controls were studied after immunocytochemical verification of the quality of the cultures. To further our
understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19
non-muscle cell types analyzed by identical methods.
Results: Many of the ~17,000 examined genes were differentially expressed (> 2-fold, p < 0.01) in control
myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or
myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD
myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis-
specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and
signal transduction. Other classes of genes, including those encoding extracellular matrix or pro-inflammatory
proteins, were upregulated in FSHD myogenic cells independent of an inverse myogenesis association. Importantly,
the disease-linked DUX4 RNA isoform was detected by RT-PCR in FSHD myoblast and myotube preparations only at
extremely low levels. Unique insights into myogenesis-specific gene expression were also obtained. For example,
all four Argonaute genes involved in RNA-silencing were significantly upregulated during normal (but not FSHD)
myogenesis relative to non-muscle cell types.
Conclusions: DUX4’s pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation
to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of
experimentally upregulated DUX4 expression at the myoblast or myotube stages. Our model could explain why
DUX4’s inappropriate expression was barely detectable in myoblasts and myotubes but nonetheless linked to FSHD.
Background
Differentiation of myoblasts to myotubes is one of the
best cell culture models for vertebrate differentiation.
However, there has been only limited expression profil-
ing of well characterized myoblast cell strains and of
myoblasts differentiated in vitro to myotubes [1-3]. In
this study, we profiled expression of control myoblasts
and myotubes as well as analogous cells from patients
with facioscapulohumeral muscular dystrophy (FSHD).
Importantly, we were able to compare control and
FSHD myoblasts and myotubes with 19 different non-
muscle cell types subjected to identical expression pro-
filing. The data are directly comparable because the
same experimental and computational techniques were
used for all the cell types. This allowed us to identify
myogenesis-specific as well as disease-associated differ-
ences in expression. We are particularly interested in
regenerative myogenesis [4], as opposed to embryonic
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myogenesis [5], because of its role in limiting atrophy
due to muscle damage, aging, and disease.
FSHD is a dominant disease whose pathogenesis is
still perplexing despite new insights into its genetic link-
age [6-8]. It is progressively debilitating and painful and
mainly affects skeletal muscle. FSHD is linked to con-
traction at 4q35 of a tandem array of 3.3-kb repeats,
D4Z4, from about 11-100 to 1-10 copies [9]. It is usually
diagnosed in the second decade, and the patient’s life-
span is generally not affected. Initially, the pathology is
limited to a small set of skeletal muscles, often asymme-
trically. There is apparently no involvement of smooth
muscle. No efficacious treatment is available.
Although other expression profiling studies of FSHD
vs. normal- or disease-control muscle biopsies have
been done [6,10-13], no clear consensus has emerged
as to the genes that lead to the muscle pathology.
Usually, only modest up- or downregulation of gene
expression was observed. FSHD is likely to involve
defects in muscle cell precursors [10]; therefore, stu-
dies of FSHD myoblasts and myotubes should also elu-
cidate normal myogenesis. In analyses of muscle tissue,
myogenesis-specific, disease-related changes in expres-
sion are obscured by the very low percentages of (acti-
vated) satellite cells. Upon expression profiling of
FSHD and control myoblasts (but not myotubes) in
2003, Winokur et al. found ~20 genes were FSHD-dys-
regulated; among them were genes involved in the
response to oxidative stress [14]. Accordingly, they
demonstrated and Barro et al. confirmed [14,15] that
FSHD myoblasts are significantly more sensitive to the
lethal effects of drug-induced oxidative stress than nor-
mal-control and disease-control myoblasts. Nonethe-
less, Barro et al. demonstrated that this
hypersensitivity did not affect growth rates or the abil-
ity of myoblasts to differentiate to myotubes. A recent
expression profiling study of FSHD and control myo-
blasts and myotubes by Cheli et al. [16] provided no
characterization of the purity of the myoblast or myo-
tube samples and paradoxically reported no muscle-
related terms among 177 functional terms for genes
with differential expression in normal-control myoblast
vs. normal-control myotube preparations, which is very
different from what we have found, as described below.
A number of 4q35 genes have been considered as can-
didates for the initially dysregulated gene during FSHD
pathogenesis, namely, FRG1, DUX4, DUX4C, ANT1
(SLC25A4), FRG2, TUBB4Q, and FAT1 [6,17-24].
Recently implicated in FSHD pathogenesis from genetic
mapping is DUX4, a 1.6-kb gene that resides within
each 3.3-kb repeat unit of D4Z4. DUX4 encodes a pro-
tein containing two homeodomains [25,26]. The protein
is strongly pro-apoptotic when highly overexpressed in
experimental models [21,27-29]. DUX4 transcripts are
normally difficult to detect probably because of hetero-
chromatinization of normal long D4Z4 arrays inhibiting
their transcription [30,31] and the lack of a polyadenyla-
tion signal within DUX4 [32], which generally leads to
DUX4 mRNA being unstable. However, in patients, a
polyadenylation signal is provided for the most distal
DUX4 gene in the D4Z4 array by a common SNP
located immediately distal to D4Z4 and specific to 4q35,
but not to the non-pathogenic 10q26 D4Z4 array [6,7].
Therefore, expression of the FSHD-linked DUX4 RNA
isoform, DUX4-fl (full length), generally requires both
array contraction at 4q35 and this SNP. Exceptions to
the requirement for array contraction for generation of
detectable DUX4-fl transcript were seen in normal testis
and in myoblasts and myotubes from patients with a
variant of FSHD called FSHD2, which is associated with
inappropriate expression of DUX4-fl RNA from 4q35
despite a lack of contraction of the D4Z4 array [8]. Both
of these exceptions may involve D4Z4 chromatin loos-
ening in normal-length arrays due to partial hypomethy-
lation of D4Z4 DNA [31,33].
DUX4-fl RNA was found in all examined FSHD myo-
tube preparations, several FSHD myoblast cell strains,
and two FSHD fibroblast cell strains, but not in the ana-
logous control cells [7,8]. However, there are still funda-
mental questions about the disease mechanisms. Firstly,
in view of the convincing genetic data linking FSHD to
the DUX4-fl RNA isoform [6-8], why was DUX4-fl RNA
expression in FSHD myoblasts and myotubes extraordi-
narily infrequent, e.g., ~ 1 in 1000 myoblast nuclei posi-
tive [8]? Why did two of five FSHD myoblast
preparations lack detectable DUX4-fl RNA by nested
RT-PCR [8] despite the finding that FSHD myoblasts
have a phenotype of hypersensitivity to oxidative stress
[14,15]? Why is FSHD essentially only a muscle-specific
disease even though FSHD fibroblasts and FSHD myo-
tubes display similar (very low) levels of DUX4-fl RNA
isoform [8]? And lastly, why do C2C12 myoblasts with
induced expression of human D4Z4-fl RNA [27,28]
undergo apoptosis or display diminished differentiation
to myotubes, unlike FSHD myoblasts, which grow and
differentiate normally? Although apoptosis has been
noted in FSHD muscle samples, it was mostly in late-
stage muscle biopsies [34].
In the current study, using exon-based expression
microarrays, we found differences in expression of
diverse categories of genes in control myoblasts and
myotubes relative to various non-muscle cell types. In
addition, FSHD muscle progenitors had a unique pat-
tern of gene dysregulation compared with analogous
control cells. A distinctive expression profile was
observed in FSHD myoblasts as well as in FSHD myo-
tubes even though DUX4-fl RNA was present at extre-
mely low levels or was undetectable in these cells.
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Methods
Cell culture
Myoblast cell strains from FSHD patients and controls
and the other cell types are described in Additional File
1, Additional File 2, and Additional File 3. FSHD myo-
blast cell strains from moderately affected muscle were
no more difficult to generate than control myoblast cell
strains. Duly signed patient consent forms were obtained
that had been approved by the Institutional Review
Boards of Tulane Health Science Center, the University
of Rochester School of Medicine, and the University of
Mississippi Medical Center in Jackson. Myoblasts were
propagated by collagenase and dispase dispersion of the
tissue, establishment of the cell strain in F10 medium
with 50% MRC-5 F10 conditioned medium, pre-plating
to remove contaminating fibroblasts, growth in the pre-
sence of 10 ng/ml bFGF and 1 μM dexamethasone, and
differentiation by limiting serum (2% horse serum for 1
day and 15% horse serum for 4-6 days), as described in
more detail in Additional File 4. Each batch of cells was
checked by immunocytochemistry for desmin (Thermo,
RB-9014-P), a marker for muscle cells. The extent of
myotube formation was determined by immunostaining
for desmin and myosin heavy chain (MF20 monoclonal
antibody from Stephen Hauschka) and determining the
percentage of nuclei in multinucleated cells.
Microarray expression analysis
Myoblast cultures at ~70% confluence and myotube pre-
parations harvested 5 - 7 days after induction of differ-
entiation were snap-frozen and stored in liquid nitrogen.
Total RNA was isolated by standard methods (TRIzol
extraction and RNeasy column, QIAGEN), that included
DNaseI digestion. RNA was checked for quality (Nano-
drop and Agilent Bioanalyzer), and 1 μg was labeled by
a standard procedure that included a riboreduction step
(Whole Transcript Sense Target labeling protocol, Affy-
metrix). The fragmented biotin-labeled cDNA was
hybridized for 16 h to Affymetrix Exon 1.0 ST arrays
and scanned (Scanner 3000 7 G, AGCC software, Affy-
metrix). After confirming the quality of the resulting .cel
files (Affymetrix Expression Console software), they
were imported into GeneSpring GX10. The data were
quantile-normalized using only core-level transcripts
(RMA) and baseline transformed to the median of all
samples. The probe sets were further filtered to exclude
ones that lie in the bottom 20th percentile across all
samples. The raw data were deposited in the GEO data-
base under series GSE26145.
qRT-PCR
RNA was isolated from snap-frozen myoblasts and myo-
tubes (RNeasy Mini kit; QIAGEN). After treatment of
the RNA (RNA Quality Indicator ≥ 9; Experion, Bio-
Rad) with DNaseI (Turbo DNA free, Ambion), cDNA
was prepared using 1 μg of total RNA (Protoscript M-
MuLV First Strand cDNA synthesis kit with Random
Primer Mix; NEB). RT-PCR was performed with SYBR
Green detection (RT² SYBR® Green qPCR master
mixes, SABiosciences; iCycler MyiQ, Bio-Rad). Unless
otherwise noted, amplifications were done in duplicate
using 20 - 40 ng of cDNA and 0.2 μM primer (Invitro-
gen) and the following parameters: 95°C, 30 s; annealing
at an optimized temperature, 30 s; 72°C, 30 s for 45
cycles. Primers were designed http://frodo.wi.mit.edu/
primer3/ and checked for the predicted specificity
http://www.ncbi.nlm.nih.gov/tools/primer-blast/. Cali-
bration curves for primer-pairs with serial 10-fold dilu-
tions of a mixture of FSHD and control myotube and
myoblast cDNAs gave slopes of -3.3 ± 0.4 and correla-
tion coefficients of ≥ 0.98. Melting curves from PCR
products were confirmed to give a single peak. The nor-
malization standard for qRT-PCR was M6PR, which,
according to the microarray data, had the following
average expression ratios for FSHD vs. control myotubes
and FSHD vs. control myoblasts: 0.97 (p = 0.9) and 1.27
(p = 0.2), respectively. M6PR was the most stably
expressed gene from a set of seven standards (M6PR,
MSN, POLR1D, PPIA, B2M, EIF4A2, and MAT2A)
tested on FSHD vs. control myotube samples
[35] http://medgen.ugent.be/~jvdesomp/genorm.
Statistical analysis
ANOVA models for the comparison of gene expression
levels across sample groups were fit using the limma
package [36] in Bioconductor http://www.bioconductor.
org, and heat maps were generated using the R gplots
package http://CRAN.R-project.org/package=gplots. The
Benjamini-Hochberg correction was used to adjust for
multiple testing, and p-values of < 0.01 were considered
significant. Chi-square tests for association and regres-
sion analyses were performed using R version 2.10
http://www.R-project.org.
Results
Cell samples for analysis
FSHD myoblasts were generated from moderately
affected muscle (See Additional File 1 for details about
samples). The control myoblasts were from two normal
individuals and one disease-control patient (sporadic
inclusion body myositis). The myoblast preparations
contained 90-98% desmin-positive cells before differen-
tiation to myotubes. Therefore, there was minimal con-
tamination with muscle-derived fibroblasts. The minor
portion of fibroblasts may nonetheless have influenced
the behaviour of the myoblasts by cell-signaling and
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might have made a contribution to the array signal,
although only a minor one, as indicated by the consis-
tent differences between FSHD and control samples.
The myotube preparations had 72-80% of the nuclei in
multinucleated myotubes (more than two nuclei per
cell) after differentiation in comparison to the myoblast
preparations with < 1% multinucleated cells (Figure 1).
The growth medium for propagating myoblasts con-
tained 10 ng/ml of basic fibroblast growth factor (bFGF)
plus 1 μM dexamethasone, as recommended in studies
of normal and FSHD myoblasts [37,38] and as used in
recent studies of DUX4 expression [7,8]. For differentia-
tion to myotubes, cells were incubated in the absence of
bFGF and dexamethasone and with replacement of the
normal 20% fetal bovine serum by 2% horse serum for
one day, and then 15% horse serum for 4-6 days. Both
the control and FSHD myotube preparations had cells
with a more normal appearance and a higher percentage
of myotubes due to the increase in the horse serum
concentration after the first day of serum limitation.
Dexamethasone improved the growth, the maximum
number of cell population doublings, and appearance of
control and FSHD myoblasts, as did regular additions of
basic fibroblast growth factor. FSHD and control myo-
blasts and myotubes looked similar by phase microscopy
(Figure 1), and the FSHD and control myoblasts grew
and differentiated to myotubes equally well.
Myogenesis-specific differences in gene expression
We used an exon-based microarray (Affymetrix Exon 1.0
ST) to profile the expression of myoblast cultures har-
vested at ~70% confluence from FSHD and control myo-
blasts and from myotube preparations (three each). Upon
differentiation of control myoblasts to myotubes, predo-
minantly upregulation of gene expression was seen (Fig-
ure 2). Setting the fold change (FC) threshold for control
myotubes vs. control myoblasts of > 2.0 at a significance
level of p < 0.01, 511 genes were upregulated and 224
downregulated; all p-values for array data were adjusted
for multiple comparisons using the Benjamini-Hochberg
correction. As expected, the group of genes that was
upregulated in control myotubes vs. myoblasts contained
a very strong overrepresentation of muscle genes. Seven-
teen out of 20 of the most overrepresented GO terms for
this set of genes were specifically related to muscle and
the other three were actomyosin structure organization,
cell adhesion, and biological adhesion (DAVID functional
analysis tool). The analogous downregulated group of
genes had only several strong associations with GO
terms, and all involved the plasma membrane.
FSHD myoblasts FSHD myotubes
Control myotubes
FSHD myotubes
Control myoblasts Control myotubes
Figure 1 Examples of myogenesis-specific immunostaining of FSHD and control myoblasts and myotubes used for the analysis. Green,
desmin; red, myosin heavy chain (MF20); blue, DAPI. The last panels in both rows were myotube preparations doubly stained with MF20 and
DAPI. The occasional small bright green or red dots are a staining artifact. Fibroblasts do not stain with the desmin antibody nor with MF20.
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Also available for determination of myogenesis-specific
gene expression was the powerful resource of our
expression profiling of 19 heterologous non-muscle cell
types as part of the ENCODE project (See Additional
File 2 for descriptions of the cell types; Crawford GE,
unpub. data). The diverse non-muscle cell cultures,
which included fibroblasts, melanocytes, hepatocytes,
and astrocytes, were profiled using the same type of
exon microarrays and identical methods as for the myo-
blasts and myotubes. An analysis of variance (ANOVA)
model was fit to determine expression differences
between myoblasts or myotubes and these non-muscle
cell types. The majority of the gene expression differ-
ences (FC > 2, p < 0.01) between control myoblasts and
non-muscle cells involved increases in expression (Fig-
ure 3A). The 20 GO terms most overrepresented among
the myoblast-upregulated genes were associated with
the plasma membrane, muscle, the actin cytoskeleton,
cell adhesion, and enzyme-linked receptor protein sig-
naling; also prominent in this set of genes were GO
terms for extracellular structure organization, calcium
ion binding, response to oxygen levels, and GTPase reg-
ulator activity. The GO terms associated with the group
of myoblast-downregulated genes were more diverse but
featured sterol metabolism, cell cycling, and cell-cell
junction. As expected, among the genes upregulated in
control myotubes vs. non-muscle cell types, muscle GO
terms predominated but extracellular structure organiza-
tion, cell adhesion, actin cytoskeleton, transmembrane
receptor, and GTPase regulator activity were also promi-
nent. For genes downregulated in control myotubes vs.
non-muscle cell types (Figure 3A), almost all the top 20
overrepresented GO terms were related to cell division.
Extensive dysregulation of gene expression in FSHD
myoblasts and myotubes
Comparing FSHD and control myoblasts, 1.7% of the
~17,000 genes represented on the microarray displayed
FC > 2.0 in expression at a significance level of p <
0.01. Remarkably, only 10% of these 295 FSHD myo-
blast-dysregulated genes were downregulated (Figure
2). At the myotube stage there were almost three times
as many FSHD-dysregulated genes (797 genes; 4.7% of
the genes on the microarray) and a much higher per-
centage was downregulated (37%). FSHD dysregulation
at the myoblast stage was significantly associated with
dysregulation at the myotube stage. For example, in
FSHD-to-control comparisons, 266 and 502 genes were
upregulated more than 2-fold in myoblasts and myo-
tubes, respectively, and 130 genes were found in both
sets of FSHD-upregulated genes (p < 0.00001, Chi-
square test). Therefore, 49% of the genes upregulated
with a FC > 2 and p < 0.01 in FSHD vs. control myo-
blast samples (3 each) were similarly upregulated in
Control myotubes vs.
control myoblasts
FSH myotubes vs. 
control myotubes





Figure 2 Differentiation of control myoblasts to myotubes involved mostly increases in gene expression that were often diminished
during FSHD myogenesis. This heat map of log2 expression values (see color key) for genes upregulated > 2-fold in control myotubes vs.
myoblasts shows that many genes that were upregulated during normal myogenesis (red in first column) were downregulated in FSHD vs.
control myotubes (green in the corresponding portion of the second column). A small fraction of these were also downregulated in FSHD vs.
control myoblasts (green in the corresponding portion of the third column).
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FSHD vs. control myotube samples (3 each). Similarly
39% of the 29 genes downregulated more than 2-fold
in FSHD vs. control myoblasts were also downregu-
lated more than 2-fold in FSHD vs. control myotubes.
It was not expected that 100% of the genes would
behave similarly because of the extensive differences in


















Myogenesis specificity for both Ctl (FC>2) & FSHD (no FC threshold) 



























No. of genes with myogenesis-specific expression in control and 
FSHD myogenic cells vs. 19 non-muscle cell types (p<0.01)
Both Ctl & FSHD cells showed myogenesis specificity (FC>2)
Only Ctl cells showed myogenesis specificity (FC>2)
Figure 3 The number of genes with myogenesis-specific expression: comparison of control and FSHD cells with 19 non-muscle cell
types. A. The number of genes with FC > 2 (p < 0.01) in comparison of both control and FSHD cells with 19 non-muscle cell types. The total
number of genes with FC > 2 (p < 0.01) for upregulation or downregulation in control myoblasts or myotubes vs. 19 diverse non-muscle cell
cultures is given in parentheses. The divisions in the bars show the overlap of the set of myogenesis-specific genes in FSHD myoblasts or
myotubes with that of the corresponding control myogenic cells. B. The number of genes with overlapping myogenesis specificity for FSHD and
control myoblasts and myotubes but relaxing the stringency for the FSHD myogenic cells to only significant myogenesis-specific differences (p <
0.01) without an FC specified while retaining the FC > 2 threshold for control myogenic cells.
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Previously reported evidence suggested that 4q35.2
genes FRG1, 4q35.1 gene ANT1 (SLC25A4), and the
5q31 gene PITX1, which were represented on our
microarrays, might be involved in FSHD [6,17-22]. In
accord with other qRT-PCR studies [23,24,39], we did
not observe dysregulation of FRG1 or PITX1. Although
detection of transcripts from FRG1 is complicated by its
cross-homology to many transcribed genomic
sequences, even in the most specific probe-sets for the
gene located in the first exon, similar signal intensities
were seen for FSHD and control myogenic cells. We did
observe that ANT1 was upregulated 2-fold in FSHD vs.
control myoblasts (p = 0.006), although not in myo-
tubes. Other 4q35.2 genes represented on the microar-
ray were FAT1 (the only 4q35.2 gene with muscle-
lineage specific DNaseI hypersensitivity sites [24]), F11,
CYP4V2, MTNR1A, ZFP42, TRIML1, and TRIML2.
They showed no differences in RNA signal between
FSHD and control myogenic cells. In addition, the mus-
cular atrophy-associated gene FBXO32 (atrogin-1)
showed no significant change in FSHD vs. control myo-
genic cells. Another atrophy-associated gene TRIM63
(MURF1) had decreased, not increased, RNA signal in
FSHD myotubes vs. control myotubes (FC = -2.3, p <
0.0001). No significant FSHD-related changes were seen
for the muscle-differentiation inhibitory MSTN (myosta-
tin), ID1, ID2, or ID3 genes.
By qRT-PCR, using mostly cDNAs not analyzed on
the microarray (Table 1 Figure 4A and 4B, Additional
File 3 for sources of cDNA, and Additional File 5 for
primers), we validated twelve sets of microarray-
determined FSHD-associated differences in expression.
Some of these genes were part of functionally related
sets that showed similar FSHD-related changes in
expression in the microarray data. For example, we
quantified MYOM1 expression by qRT-PCR (Table 1),
and, according to the microarray data, the muscle-asso-
ciated myomesin genes, MYOM1, MYOM2, and
MYOM3 were all downregulated in expression in FSHD
vs. control myotubes (FC = - 8.9, -8.1, and -3.8, respec-
tively, each p < 0.0005). Nonetheless, these genes still
had significantly more expression in FSHD myotubes
than in the non-muscle cell samples (FC = 3.2, 1.5, and
3.8, respectively, each p < 0.0001).
The gene chosen for normalization of the qRT-PCR
data was M6PR on the basis of its essentially identical
average expression levels in control and FSHD myo-
blasts and myotubes, as determined from the microarray
expression data. The often-used GAPDH, PPIA, and
B2M genes were not optimal standards because of diffi-
culty in finding unique primer-pairs due to closely
related genes or pseudogenes elsewhere in the genome
(GAPDH and PPIA) or FSHD-linked differences in
expression levels (B2M and several GAPDH-related gly-
colytic enzymes). Our finding that ~800 genes showed
more than 2-fold differences in expression in FSHD vs.
control myotubes (p < 0.01) and many more showed
significant differences that were less than 2-fold indi-
cates the importance of using expression profiling data
to choose gene standards for qRT-PCR that will not
give artifacts in determining relative expression levels of
test genes.












PCOLCEa 5.9 4E-05 3.5 0.04 5 6
RUVBL2 2.2 5E-04 1.7 0.01 7 8
TGFB2 -2.8 4E-04 -1.9 0.02 9 8
EIF2C2 -1.6 0.007 -1.6 0.03 8 8
Myotubes
BGN 11.0 < 1E-06 16.8 0.04 8 9
DCN 6.4 6E-04 7.5 0.01 8 9
PCOLCE 10.2 < 1E-06 3.7 0.03 6 7
MYOM1 -8.9 2E-06 -2.9 0.05 4 4
SFRS9 3.5 < 1E-06 3.5 0.01 6 6
CAPG 3.0 0.002 3.2 0.02 8 9
IGFBP6 2.5 0.02 3.5 0.01 8 9
FRAS1 -3.02 0.001 -2.2 0.001 4 4
aFull gene names and primer-pairs are given in Additional File 5 TableS4
bFC, fold change in RNA signal was determined by exon microarray analysis or qRT-PCR
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We also assayed relative levels of DUX4-fl RNA, the
RNA isoform associated with FSHD, using very high
amounts of cDNA as template, namely, 400 ng, as per
the method of Lemmers et al. [7]. We could detect
DUX4-fl RNA in some of the FSHD myotube and myo-
blast samples (Figure 4C and 4D). None of the control
myoblasts and myotubes gave appreciable signal. The Ct
values from positive FSHD myoblasts and myotubes
were usually much higher, namely, 33-36, than for the
other tested amplicons with the same cDNAs despite
the use of 10-20 times more cDNA for the DUX4 RT-
PCR. We do not have microarray results for comparison
to the DUX4 RT-PCR data because DUX4 is not repre-
sented on the microarray due to its extensive cross-
hybridization in the genome [40].
Dampening of muscle-specific transcription changes in
FSHD vs. control myogenic cells
Downregulated expression in FSHD vs. control myogenic
cells was associated with upregulated expression in control
myogenic cells vs. non-muscle cell types (p < 0.01; Figure
5). The analogous inverse relationship was seen for genes
upregulated in FSHD vs. control myogenic cells. Often,
the downregulation in FSHD myoblasts or myotubes rela-
tive to the analogous control cells was a dampening of
myogenesis-linked expression increases, rather than the
absence of these normal myogenesis-related expression
changes (See Additional File 6 and Additional File 7 for
fitted regression analysis). This dampening of myogenesis-
specific expression is evidenced by the finding that a much
higher percentage of genes showed myogenesis specificity
A B
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Figure 4 Examples of qRT-PCR validation of microarray expression data and DUX4 expression by RT-PCR. A. and B. By qRT-PCR on 20 -
40 ng of cDNA template, the relative expression of representative genes in FSHD vs. control myoblast or myotube samples from different
individuals was determined for representative genes that displayed significant FSHD-linked differences on the microarray (Table 1). qRT-PCR
signals for the test amplicons were normalized to those of M6PR. The average fold-changes deduced from the qRT-PCR and the microarray
analysis are shown, and the p-values for the FSHD/control differences are indicated. C. and D. To detect DUX4-fl RNA (fl, full-length isoform,
associated with FSHD), 400 ng of cDNA was used for real-time PCR as previously reported [7]; 20 - 40 ng of cDNA was used for the other
amplicons. Results from different individual FSHD and control cell strains are shown. The samples used for DUX4 RT-PCR were the same as those
used for qRT-PCR validation of microarray results.
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in FSHD myogenic cells vs. non-muscle cell types when
the expression differences had to meet the criterion of p <
0.01 but no fold-change threshold of 2.0 was set as for the
control myogenic cells (Figure 3B vs. 3A). Examples of
genes with dampening of myogenesis-specific expression
changes in FSHD cells are shown in Figure 6B. However,
other myogenesis-associated genes, e.g., the critical myo-
genesis-specific transcription factors MYOD1 and MYOG,
displayed no change in RNA levels in FSHD vs. control
myoblasts or myotubes (Figure 6A). Some genes were dys-
regulated in FSHD myoblasts or myotubes but did not
exhibit inverse expression changes in myogenic vs. non-
muscle cells. For example, 5% of the genes upregulated in
FSHD vs. control myotubes (FC > 2, p < 0.01) were also
upregulated in control (and FSHD) myotubes vs. non-
muscle cell types. In this group there was an overrepresen-
tation of genes associated with inflammation or encoding
extracellular proteins.
Transcriptional dysregulation in FSHD
Some transcription regulatory genes were significantly
dysregulated in FSHD vs. control myogenic cells (Figure
Figure 5 Inverse relationships between myoblast- and myotube-specific gene expression changes and FSHD-specific changes. A. Genes
up- or downregulated in FSHD vs. control myoblasts often showed opposite changes in expression in control myoblasts vs. 19 non-muscle cell
types. This heat map of log2 expression ratios for genes upregulated > 2-fold (p < 0.01) in FSHD vs. control myoblasts illustrates that these
genes were often downregulated in control myoblasts vs. diverse non-muscle cell cultures and that there was the converse relationship for
genes downregulated in FSHD vs. control myoblasts and upregulated in control myoblasts vs. non-muscle cell cultures. Both associations were
significant (p < 0.01). B. This heat map is analogous to that of Panel A except that it is for myotubes instead of myoblasts.
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7). MEF2A, RB1, MKL2, and KLHL31, which are asso-
ciated with transcription control during myogenesis
[41,42], were downregulated in FSHD vs. control myo-
tubes. FSHD myotubes relative to those of controls dis-
played upregulation of JUNB and CREB3L1, which are
transcription factors with protective roles for muscle or
cellular stress [43,44]. In FSHD vs. control myoblasts,
DPY30, RUVBL2, DRAP1, PMF1, HMGN3, and LMO3
were among the genes involved in the control of tran-
scription that were significantly dysregulated.
To obtain additional evidence for dysregulation of
steady-state RNA levels in FSHD being governed, in
part, by differential activity of transcription factors, we
analyzed the distribution of predicted transcription fac-
tor binding sites (TFBS) among the promoter regions of
a set of 826 genes. These were approximately equally
divided between genes that were upregulated and those
that were downregulated in FSHD vs. control myotubes.
Four of the 126 analyzed TFBS motifs were significantly
skewed toward either FSHD up- or downregulation (p <
0.01; Table 2). MEF2A and E4BP4 DNA-binding motifs
were enriched among FSHD-downregulated genes,
which is consistent with the downregulation of MEF2A
RNA in FSHD vs. control myotubes (Figure 7) and its
role in myogenesis and the role of E4BP4/NFIL3 as a
transcription repressor. The motifs for TP53, which is
associated with inflammation, and PPARG, which is
associated with stress response and lipid metabolism,
were significantly correlated with genes that were upre-
gulated in FSHD vs. control myotubes. There was no
change in TP53 RNA levels and only a ~1.5-fold
increase (p = 0.02) in PPARG RNA levels; however,
expression of the protein products, their modification,
and interactions might have changed in FSHD cells.
Evidence for post-transcriptional dysregulation of RNA
levels in FSHD
Genes encoding the components of the RNA-induced
silencing (RNAi) machinery, including all four Argo-
naute genes, were significantly downregulated in FSHD
vs. control myotubes and two of them were also down-
regulated in FSHD vs. control myoblasts (Figure 7). The
downregulation of EIF2C2 (Argonaute 2) in FSHD myo-
blasts was confirmed by qRT-PCR (Figure 4A). Surpris-
ingly, these genes showed significantly higher expression





change P -value        Fold change P -value     
Fold 
change P -value   
A. Examples of muscle-associated genes without significant dysregulation of expression in FSHD myogenic cells
MYOD1  myogenic differentiation 1 Mb 12 <1E-06 15 <1E-06 1.3 0.42
MYOG  myogenin (myogenic factor 4) Mt 59 <1E-06 56 <1E-06 -1.1 0.94
MYF5  myogenic factor 5 Mb 255 <1E-06 233 <1E-06 -1.1 0.84
MYF6  myogenic factor 6 (herculin) Mb 19 <1E-06 21 <1E-06 1.1 0.92
CHRNA1  cholinergic receptor, nicotinic, alpha 1 (muscle) Mt 131 <1E-06 115 <1E-06 -1.1 0.60
KBTBD10  kelch repeat and BTB (POZ) domain containing 10 Mt 336 <1E-06 243 <1E-06 -1.4 0.27
TTN  titin Mt 590 <1E-06 304 <1E-06 -1.9 0.31
B. Examples of muscle-associated genes with significant downregulation of expression in FSHD myogenic cells
CLCN4  chloride channel 4 Mt 5.2 <1E-06 1.6 0.003 -3.1 5E-05
MYPN  myopalladin Mt 40 <1E-06 9.0 <1E-06 -4.4 8E-05
SGCG  sarcoglycan, gamma Mt 65 <1E-06 12 <1E-06 -5.4 0.002
SRL  sarcalumenin Mt 83 <1E-06 15 <1E-06 -5.7 0.002
MYL1  myosin, light chain 1, alkali; skeletal, fast Mt 112 <1E-06 19 <1E-06 -5.9 0.006
NRAP  nebulin-related anchoring protein Mt 4.4 <1E-06 -1.4 0.08 -6.0 <1E-06
MYH7  myosin, heavy chain 7, cardiac muscle, beta Mt 48 <1E-06 6.1 <1E-06 -7.9 5E-05
XIRP2  xin actin-binding repeat containing 2 Mt 35 <1E-06 4.0 3E-05 -8.8 4E-05
MYOT  myotilin Mt 21 <1E-06 1.8 0.001 -11.7 <1E-06
ATP1B4  ATPase, Na+/K+ transporting, beta 4 polypeptide Mt 103 <1E-06 8.5 <1E-06 -12.2 <1E-06
MYBPC1  myosin binding protein C, slow type Mt 100 <1E-06 4.7 <1E-06 -21.3 <1E-06
FSHD-specificityControl  myogenesis FSHD myogenesis
Mb or Mt/Non-muscle 
cells
 Mb or Mt/Non-muscle 
cells
      FSH vs. Ctl Mb or Mt 
Figure 6 Some muscle-associated genes are downregulated in FSHD myogenic cells while others are not. Fold changes in RNA signal
were determined by identical expression profiling of FSHD and control myoblast and myotube preparations and 19 diverse non-muscle cell
types (See Additional File 1 and Additional File 2 for detailed descriptions of samples). All p-values for microarray data were adjusted for multiple
comparisons; pink, significantly upregulated at p < 0.01; green, significantly downregulated at p < 0.01. Myotube (Mt) data are shown for the
genes with much stronger expression at the myotube stage than at the myoblast stage. Myoblast data are given for MYOD1, MYF5, and MYF6.
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Fold change
FSH/Ctl Ctl/non-muscle FSH/non-muscle
Gene Gene description Myob Myot Myob Myot Myob Myot
Transcription factors, chromatin modification and remodeling proteins
KLHL31 Kelch-like 31 (Drosophila) -1.1 -7.1 1.9 23.5 1.7 3.3
LMO3 LIM domain only 3 -9.6 -5.6 33.6 4.1 3.5 -1.4
MYF6 myogenic factor 6 (herculin) 1.1 -3.3 19.5 24.9 20.9 7.5
MEF2A Myocyte enhancer factor 2A -1.1 -2.3 2.5 7.5 2.3 3.3
RB1 Retinoblastoma 1 -1.4 -2.1 2.6 3.2 1.9 1.5
MKL2 MKL/myocardin-like 2 -1.1 -1.9 1.4 2.1 1.2 1.1
DPY30 Dpy-30 homolog 3.2 3.5 -2.1 -2.8 1.5 1.3
CREB3L1 cAMP responsive element binding 3L1 1.7 2.7 1.4 1.6 2.4 4.3
RUVBL2 RuvB-like 2 (E. coli) 2.2 2.2 -1.9 -3.1 1.2 -1.4
MEIS2 Meis homobox 2 1.6 2.1 -2.1 -2.3 -1.3 -1.1
DRAP1 DR1-associated protein 1 2.7 2.1 -1.8 -2.6 1.5 -1.3
JUNB Jun B proto-oncogene 1.2 1.9 -1.5 -1.3 -1.2 1.4
HMGN3 HMG nucleosomal binding domain 3 2.6 1.8 -1.7 1.5 1.5 1.3
VPS72 Vacuolar protein sorting 72 homolog 2.2 1.8 -2.3 -1.8 1.0 1.0
PMF1 Polyamine-modulated factor 1 1.9 1.6 -1.5 -1.6 1.3 1.0
RNAi machinery
EIF2C1 Euk. transln. initiation factor 2C, 1 -1.1 -1.5 1.2 1.4 1.1 -1.1
EIF2C2 Euk. transln. initiation factor 2C, 2 -1.6 -1.8 1.9 2.0 1.2 1.1
EIF2C3 Euk. transln. initiation factor 2C, 3 -1.5 -1.6 2.4 2.5 1.6 1.6
EIF2C4 Euk. transln. initiation factor 2C, 4 -1.1 -2.3 1.4 3.2 1.3 1.4
DICER Dicer 1, ribonuclease type III -2.1 -1.9 2.2 1.9 1.0 1.0
DDX6 DEAD box polypeptide 6 -1.5 -1.7 1.6 1.7 1.1 1.0
TNRC6B Trinucleotide repeat containing 6B -1.1 -1.6 1.7 2.2 1.5 1.4
Figure 7 Transcription control and RNAi machinery genes dysregulated in FSHD cells. Pink or green highlighting indicates significant up-
or downregulation, respectively, for the indicated comparison at p < 0.01; italics, p < 0.001. The FSHD/Ctl difference in expression for MEIS2 was
the exception with p = 0.02. KLHL31, RUVBL2, and EIF2C2 had been tested and validated for FSHD-associated dysregulation by qRT-PCR (Table 1).
Table 2 TFBS motifs associated preferentially with FSHD up- vs. downregulated genes in myotubes.














FSH upreg. FSH dnreg.
MEF2A 39 101 0.4 < 0.0001 PI3K signaling, 8 genes muscle phenotype, 16 genes
E4BP4 16 42 0.4 0.008 cell adhesion, 5 genes, GO:0007155 none
PPARG 100 43 2.3 0.0001 extracellular matrix, 13 genes, GO:0031012;
arachidonic acid, 15 genes
cardiac hypertrophy, 7 genes
p53 84 37 2.3 0.0009 inflammation, 29 genes; superoxide, 29 genes Activation of cAMP-
dependent PKA, 5 genes
aPredicted transcription factor binding site motifs (TFBS) in the upstream (promoter) region for 403 and 423 genes that displayed the strongest up- or
downregulation (p < 0.01), respectively, in FSHD vs. control myotubes. These sites were identified by GeneCards http://genecards.org and were analyzed by Chi-
square tests for association with FSHD up- vs. downregulation in myotubes. Of the 126 TFBS scored, the four shown in this table had the strongest association
with either FSHD up- or downregulated genes. For PPARG, PPARG1 and PPARG2 motifs were pooled.
bFunctional annotation from GeneDecks http://genecards.org
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(Figure 7). In FSHD myogenic cells compared with the
non-muscle cell types, these genes were not downregu-
lated; most of them were just not upregulated.
Exon-based microarrays can reveal the presence of cell
type-specific differences in RNA isoforms from a given
gene by analysis of exon-normalized probe data instead
of the gene-normalized data described above. By gel
electrophoresis, we examined oligo(dT)23-primed RT-
PCR products (0.2 - 0.5 kb) from five of the genes for
which the exon-normalized array data suggested FSHD-
specific RNA isoforms. None of these representative
genes (FAT1, SCUBE3, ILF3, TFPI2, or SFRS7) was vali-
dated as giving the predicted FSHD-specific differences
in RNA sizes. In addition, we looked for previously
reported FSHD-associated RNA isoforms from FXR1P,
TNNT3, and MTMR1 [17,45] but did not see any evi-
dence for them in our cell populations.
Functional terms associated with genes dysregulated in
FSHD myoblasts and myotubes
A bioinformatics analysis was done to look for func-
tional terms associated with genes significantly dysregu-
lated in FSHD myoblasts or myotubes (p < 0.01).
Functional terms overrepresented among FSHD-upregu-
lated genes (e.g., mitochondrial terms, extracellular
matrix, Rho) were mostly very different from those for
FSHD-downregulated genes (e.g., myofibril, RNA-
induced silencing complex; Table 3). Many of the genes
that were upregulated in both FSHD myoblasts and
myotubes were related to the response to cell stress,
such as GSTP1, HSP90AA1 HSP90AB1 HSPA1A,
HSPC152, and DNAJC4 (See Additional File 8 for gene
lists). However for cell stress genes, as for most of the
overrepresented functional terms among FSHD-dysregu-
lated genes, the up- or downregulation in FSHD vs.
control myogenic cells was often associated with down-
or upregulation, respectively, in control myogenic cells
vs. non-muscle cells. This is illustrated in Additional
File 9 for FSHD-dysregulated pro- and anti-apoptosis
genes.
Discussion
Our study is the first to examine in parallel many differ-
ent human cell types and compare them to well-charac-
terized FSHD and control myoblasts and myotubes and
thereby demonstrate extensive FSHD-linked dysregula-
tion of gene expression. Importantly, we confirmed by
RT-PCR that the disease-associated RNA isoform of
DUX4, DUX4-fl RNA, is expressed at extraordinarily
low levels in FSHD (but not detectable in control) myo-
blasts and myotubes despite the hundreds of genes dys-
regulated more than 2-fold in FSHD vs. control
myoblasts and myotubes. Our findings of extremely
infrequent expression of DUX4-fl RNA in FSHD
myoblasts and myotubes and undetectable levels in
some of these FSHD cell populations are consistent with
previous reports. This transcript was detected in only
~1 out of 1000 FSHD myotube nuclei and was observed
less frequently in FSHD myoblasts than in myotubes [8].
Similarly, its detection by one round of real-time PCR
required much higher-than-normal amounts of FSHD
myotube cDNA [7]. Because FSHD myoblasts and myo-
tubes had a strong transcription dysregulation profile
(this study) and FSHD myoblasts are hypersensitive to
oxidative stress [14,15], if DUX4 is the first pathologi-
cally dysregulated gene in FSHD, then it must be
expressed much more extensively, but transiently, at an
earlier stage in myogenesis. We propose that DUX4-fl
RNA initiates a cascade of gene dysregulation at or
before activation of FSHD satellite cells to form myo-
blasts (Figure 8). DUX4-fl transcripts in myotubes and
myoblasts would then represent a rare re-activation of
inappropriate DUX4 expression that is not central to
pathogenesis. This model contrasts with the current
Table 3 Some pathways and functional terms









RNA-induced silencing complex Mt 4 dn 0.80
Mb 1 dn 0.20
Fatty acid elongation in mitochondria Mb 7 up 0.44
Mt 2 up 0.13
Extracellular matrix Mt 35 up, 1 dn 0.30
Mb 4 up, 2 dn 0.05
NRF2-mediated oxidative stress response Mt 15 up, 7 dn 0.13
Mb 7 up 0.04
HIF1a Signaling Mt 6 up, 7 dn 0.12
Mb 5 up 0.05
Regulation of actin-based motility by
Rho
Mt 9 up, 3 dn 0.10
Mb 6 up 0.07
Mitochondrial matrix Mt 18 up, 5 dn 0.11
Mb 22 up, 1 dn 0.11
Oxidative phosphorylation Mt 18 up 0.16
Mb 11 up 0.09
Induction of apoptosis Mt 13 up, 5 dn 0.09
Mb 8 up, 2 dn 0.05
Anti-apoptosis Mt 16 up, 3 dn 0.10
Mb 4 up 0.02
aOverrepresented functional terms for genes up- or downregulated (p < 0.01)
in FSHD vs. control myoblasts (Mb) or myotubes (Mt) were identified by
bioinformatics programs. Details and the names of the dysregulated genes are
given in Additional File 8 Table S5.
bThe number of genes for a given pathway or GO-term that were up- or
downregulated in FSHD vs. control myogenic cells/the total number of genes
for that pathway or GO-term that were included in the microarray.
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emphasis on the rare expression of DUX4-fl RNA in
myoblasts and myotubes.
Induction of DUX4-fl transcription in transduced
C2C12 myoblasts caused apoptosis; inhibited differentia-
tion to myotubes; gave dramatic changes in cell shape;
and, even at sublethal concentrations, inhibited tran-
scription of MYOD1 and MYOG and increased that of
CDKN1A (p21) [27]. In addition, DUX4-fl RNA injected
into Xenopus or zebrafish embryos is highly cytotoxic
[21,46]. In contrast, we found only minimal apoptosis in
FSHD myoblasts and myotubes and no more than in
controls (~5% of nuclei as detected by staining with
ethidium bromide and acridine orange [47] and no
internucleosomal fragmentation of DNA [48], data not
shown). In our comparison of FSHD and control
myotubes, more anti-apoptotic than pro-apoptotic
changes in gene expression were seen and the dysregula-
tion of most of these genes can be explained by FSHD-
associated changes in the normal myogenesis program
(See Additional File 9). The good growth and efficient
differentiation to myotubes of FSHD myoblasts observed
by us and others [15] are consistent with our finding
that the myogenic regulatory factors MYOD1, MYOG,
MYF5, and MYF6 were equally highly expressed at the
RNA level in FSHD vs. control myoblasts and only
MYF6 was significantly downregulated in FSHD vs. con-
trol myotubes. This result argues against FSHD-related
differences in posttranscriptional processing of the pro-
ducts of these four genes in myoblasts because their
expression is autoregulatory [49-52]. In addition, we
¾More gene dysregulation but still formation of myotubes is efficient
¾ Rare myotube nuclei have re-activation of DUX4-fl transcript  formation
Dysregulation of TGFɴ & 
other signaling pathways
• Transcription dysregulation, including for TF-encoding genes
• Post-transcriptional dysregulation,  including less of the normal 
myogenesis-linked upregulation of the RNAi machinery 
ј extracellular 
matrix proteins
• ј in expression of mitochondrial protein genes
• Oxidative stress response 










Many cells may have transient FSHD-linked expression of DUX4-fl RNA
FSHD  satellite cells
Activation*
Figure 8 Proposed scheme for FSHD pathogenesis in myoblasts. This cartoon shows some of the main regulatory changes at the myoblast
stage that may be determining the FSHD-specific gene expression profile in myoblasts and myotubes. DUX4-fl RNA is found at extremely low
levels in FSHD and control myoblasts and myotubes but not in the corresponding control cells. The double-headed arrows indicate that these
regulatory changes can reinforce each other. TF, transcription factors. RNAi, RNA interference; *, the activation of DUX4-fl expression in FSHD at
the satellite cell stage is proposed to occur at or before activation of FSHD satellite cells and is not yet tested.
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observed no differences between FSHD and control
myogenic cells in RNA levels for E-box protein hetero-
dimer partners of these myogenic regulatory factors
(data not shown). In support of our model of the pro-
posed non-cytotoxic expression of DUX4 very early in
myogenesis (Figure 8), the early-myogenesis transcrip-
tion factors PAX3 and PAX7 can partly counteract the
deleterious effects of overexpression of DUX4 in C2C12
cells [27]. Moreover, DUX4-fl transcripts are normally
rather abundant in testis [8].
Previously used arrays for transcription profiling of
well-characterized FSHD and control myogenic samples
[10-12,14] did not have multiple probe-sets per exon for
each transcript nor probes for exons other than the 3’
exon and so are much less representative of the tran-
script populations. Given this major difference and the
use of muscle tissue rather than myoblasts (a very
minor component of muscle) in most of the previously
published FSHD RNA profiling studies, it is not surpris-
ing that there was only minimal overlap between genes
reported as dysregulated in FSHD in previous studies
and genes that we observed to be dysregulated in FSHD
vs. control myogenic precursors. An example of such
infrequent overlap is the upregulation of the vascular
smooth muscle-associated CTGF, ENG, and TAGLN
genes in FSHD vs. control muscle [12] and, in this
study, in FSHD vs. control myotubes (2- to 3-fold upre-
gulation, p < 0.001 for all comparisons). In the previous
expression profiling of well-characterized FSHD and
control myoblasts, a “vacuolar/necrotic phenotype” was
noted for “the majority” of FSHD myoblasts, which were
“markedly swollen.” That morphological phenotype
might be due to FSHD myoblasts being more sensitive
to stress than analogous controls. Because we used only
moderately affected muscle to generate myoblast cell
strains and FSHD is characteristically a slowly progres-
sive disease in which disease muscle biopsies look rela-
tively normal at the time of clinical onset [53], the
normal appearance of FSHD myoblasts and myotubes
under our optimized growth conditions is likely to be
relevant to understanding pathogenesis. Moreover, the
equally good generation, propagation, growth, and dif-
ferentiation of FSHD and control myoblasts also argue
against the possibility that we selected a non-representa-
tive sub-phenotype of FSHD myoblasts. Similarly, these
observations fit the high degree of correlation of the
overall expression profiles of all the FSHD and control
myogenic samples with each other when compared to
the 19 non-muscle cell populations despite the hundreds
of significant more-than-two-fold differences in RNA
signal for individual genes in comparisons of FSHD and
control myoblasts or myotubes.
There was a recent report by Cheli et al. [16] about
exon array-based expression profiling of FSHD and
control myoblasts and myotubes but it included no
characterization of the percentage myoblasts in the stu-
died cell populations nor the efficiency of differentiation
to myotubes. The extent of contamination of untrans-
formed myoblast cultures with non-muscle cells can
vary dramatically between different myoblast cell strains
and even at different passage numbers and, thereby,
have a major impact on expression profiling. Cheli et al.
reported < 4% overlap between several hundred genes
with dysregulation in FSHD vs. control cells at the myo-
blast stage and those dysregulated at the myotube stage,
unlike the present study in which we found 48% overlap
between genes with FSHD dysregulation (p < 0.01, FC >
2) in myoblasts and myotubes. The difference in the
results from the study of Cheli et al. and the present
study might be due to the unknown percentage of cells
that differentiated in their experiment vs. 72-80% in
ours.
Our analysis of normal myogenesis from a comparison
of expression profiles of control myoblasts and myo-
tubes and 19 non-muscle cell types indicated the promi-
nent role of upregulation of genes generally involved in
the actin cytoskeleton, organization of the extracellular
matrix, cell adhesion, and GTPase regulator activity, in
addition to the expected muscle-specific genes. One
unexpected functional class of genes that was more
highly expressed in control myoblasts and myotubes
than in non-muscle cells was the RNA silencing
machinery genes. These same RNA silencing machinery
genes were lacking upregulation during FSHD myogen-
esis, which may contribute to the observed excess of
FSHD-upregulated vs. FSHD-downregulated genes in
myogenic precursors.
Our expression profiling of FSHD vs. control myo-
blasts suggests an explanation for the FSHD myoblasts’
hypersensitivity to external oxidative stress [14,15] as
well as an imbalance in the redox system in muscle
[54]. The observed FSHD-related upregulation of many
transcripts from oxidative phosphorylation genes could
result in an increase in endogenous reactive oxygen spe-
cies and might eventually result in apoptosis in some
severely affected muscles. Accordingly, increases in
H2O2 were seen in FSHD vs. control muscle [54] and
upregulation of some mitochondrial oxidative phosphor-
ylation proteins and oxidative stress-response proteins
was observed in affected and also in unaffected FSHD
skeletal muscle vs. normal-control muscle [20]. Simi-
larly, we found FSHD-associated upregulation of RNA
for oxidative stress-response and oxidative phosphoryla-
tion proteins, including several of the same proteins
(SOD1 and HSPB1) whose FSHD-upregulation was seen
in muscle [20]. The hypothesized inappropriate expres-
sion of DUX4 very early during regenerative myogenesis
would help explain why even unaffected muscle showed
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these abnormalities in protein levels [20] and why myo-
blasts from unaffected FSHD muscle samples displayed
an FSHD-associated hypersensitivity to oxidative stress
[15]. Moreover, it would be consistent with our finding
that myoblast cell strains from diverse, moderately
affected FSHD muscle samples displayed FSHD-related
changes in gene expression.
The most prominent feature of the transcription dys-
regulation in FSHD myoblasts and myotubes was the
decrease in the up- and downregulation of RNA levels
associated with normal myogenesis, which can account
for most of the FSHD-related dysregulation. Expression
profiling of other muscular dystrophies [55-58] has not
revealed such a widespread dampening of normal myo-
genesis-associated transcription changes in various
functional gene categories. Some classes of genes,
including those encoding extracellular matrix or pro-
inflammatory proteins, were strongly enriched in
FSHD-upregulation in myogenic cells independent of
any inverse myogenesis association. The proliferation
of FSHD myoblasts and their differentiation to myo-
tubes in vitro was unaffected by these changes in gene
expression. Apparently, there is also not a large dis-
ease-related depletion of satellite cells in FSHD
patients because of the above-mentioned finding that
generating myoblast cell strains from moderately
affected muscle biopsies of FSHD patients was no
more difficult than from control muscle. Moreover,
although Reed et al. [59] observed abnormal spatial
relationships of the sarcolemma with the underlying
contractile apparatus in affected FSHD muscle, the
structure of the contractile apparatus itself appeared
normal. The observed FSHD-associated gene dysregula-
tion may have been heightened in the FSHD myoblasts
and myotubes relative to their in-vivo counterparts due
to the effects of cell culture and the use of the myo-
blast-stimulatory [37,38] dexamethasone in the culture
medium for both FSHD and control myoblasts [60,61].
If extensive cell culture promoted increased gene dys-
regulation in FSHD myoblasts, this could be relevant
to the disease in vivo because usually it is only slowly
progressive. In addition, glucocorticoids are relevant in
vivo because of the effects of endogenous glucocorti-
coids in traumatic or muscle wasting conditions [62,63]
and the therapeutic use of glucocorticoids. Moreover, if
only a small fraction of the extent of gene dysregula-
tion that we saw exists in vivo, this could lead to atro-
phy by interfering with effective regenerative
myogenesis. For example, all three of the skeletal mus-
cle-associated myomesin genes showed downregulation
in FSHD vs. control myotubes of about 4 to 9 fold, and
the products of these genes bind to other muscle struc-
tural proteins in a dose-dependent manner as major
components of the myofibrillar M-band.
It is not yet clear whether the dysregulated gene
expression in FSHD myoblasts is due to disease-related
differences in transcription regulatory or RNA-proces-
sing proteins, cell signaling (e.g., TGFb or RHO/mTOR
pathways [64,65]), indirect effects on transcription from
overexpression of extracellular proteins [66], indirect
effects of mitochondrial dysfunction [67], subtle differ-
ences in timing of expression of some myogenesis-speci-
fic gene(s), and/or disease-specific epigenetic differences.
At the myotube stage, the increase in the number of
genes that were dysregulated in FSHD cells may be
partly due to the FSHD-associated decreases in expres-
sion of the transcription regulatory MYF6 and MEF2A
genes and abnormal increases in expression of MEIS2
after induction of differentiation to myotubes.
Conclusions
Given the extremely low rate of FSHD-associated inap-
propriate expression of DUX4 at the myoblast, myotube,
and muscle stages, many of the FSHD-dysregulated
transcription-regulatory or cell signaling genes revealed
by our expression profiling may be more effective tar-
gets for developing pharmacologically-based or gene
therapy-based treatment of FSHD than DUX4 itself. Our
findings point to FSHD being a differentiation-asso-
ciated disease, and so study of this enigmatic muscular
dystrophy is likely to elucidate new aspects of normal
myogenesis as well as pathogenesis. In addition, our
comparison of transcription profiles of control myo-
blasts and myotubes and those of 19 other cell types
that were examined identically showed how very exten-
sive gene expression changes are upon formation of
myoblasts and upon their differentiation to myotubes.
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up- or downregulated in FSHD myotubes because of dampening of their
normal myogenesis-associated changes in expression.
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